Advocacy Group Launches National Campaign to Reform 340B Drug Pricing Program
ADAP Advocacy initiates a nationwide campaign questioning the accountability and transparency of the 340B Drug Pricing Program, drawing parallels to pre-2008 financial market oversight and highlighting potential systemic issues in healthcare.
ADAP Advocacy has launched a national advocacy campaign calling for reforms to the 340B Drug Pricing Program, challenging the current structure of what is the nation's second-largest federally sponsored drug program.
The campaign, titled '340B Too Big To Fail', aims to draw attention to concerns about the program's lack of meaningful accountability and transparency, particularly among large hospital systems. Brandon M. Macsata, CEO of ADAP Advocacy, compared the current state of the program to the financial markets before the 2007-2008 economic collapse, suggesting similar risks of minimal federal oversight.
The advocacy group's commercial, airing in the Washington, DC metropolitan area while Congress is in session, will run through the end of the year. The campaign will focus on critical issues such as hospitals' declining charity care, escalating healthcare executive compensation, and the growing burden of patient medical debt.
By highlighting these concerns, ADAP Advocacy seeks to prompt a comprehensive review of the 340B Drug Pricing Program and encourage legislative action to ensure its integrity and effectiveness in serving patients' healthcare needs.